Thus, our data suggested that although JAK/STAT3 signaling could be upregulated by TME stromal cells and could influence CSC behaviors, targeting the signaling will be unlikely to be beneficial to thyroid cancer patients. The gene discussed is STAT3; the disease is thyroid gland carcinoma.